Boston Scientific shares slide on cautious 2026 revenue forecast

Feb 4 (Reuters) - Boston Scientific Corp forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, overshadowing a strong fourth-quarter performance and sending its shares down more than 11% in premarket trading.

The medical-device maker projected 2026 adjusted earnings per share of $3.43 to $3.49, with the midpoint at $3.46 falling short of the average analyst estimate of $3.47 per share, according to LSEG data.

The subdued outlook comes as the Massachusetts-based company prepares to integrate its $14.5 billion acquisition of Penumbra, announced last month.

The company also expects organic revenue growth of 10% to 11% for 2026, marking a deceleration from the 15.8% organic growth recorded in 2025.

The cautious guidance overshadowed the coronary stents and pacemaker manufacturer's fourth-quarter results, which surpassed analyst expectations.

The company reported adjusted earnings of 80 cents per share, beating the consensus estimate of 78 cents, while revenue of $5.29 billion edged past forecasts of $5.28 billion.

For the first quarter of 2026, Boston Scientific expects adjusted earnings of 78 cents to 80 cents per share, compared with the analyst consensus of 79 cents.